Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
SY-104 / Syena
NCT06066359: Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma	Recruiting	1/2	44	US	Fludarabine phosphate, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Neosar®, NY-ESO-1 TCR/IL-15 NK	M.D. Anderson Cancer Center	Myeloma	08/26	08/28
NCT06083883: Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1	Suspended	1	44	US	Fludarabine phosphate, Fludarabine, Fludara®, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide, Cytoxan®, Neosar®	M.D. Anderson Cancer Center	Synovial Sarcoma, Myxoid/Round Cell Liposarcoma	11/26	11/28